Bioequivalence Studies Reporting Rule Will Boost Submissions By 10% – FDA

A proposed rule to require ANDA sponsors to submit all bioequivalence studies they complete would increase annual BE study reports by 10%, FDA estimates

More from Archive

More from Pink Sheet